[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fibrous-dysplasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fibrous-dysplasia":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,79,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100641702","clinical-evaluation-of-patient-specific-3d-printed-titanium-implants-for-facial-reconstruction-100641702",false,"NCT07654647","Clinical Evaluation of Patient-Specific 3D-Printed Titanium Implants for Facial Reconstruction.","Evaluation of the Effectiveness of Patient-Specific 3D-Printed Titanium Facial Implants in the Reconstruction and Aesthetic Correction of Facial Defects: A Clinical Study","3DFACE","Inclusion Criteria:\n\n* Age 18 years or older.\n* Presence of facial bone defects resulting from cystic or tumoral osteolytic lesions.\n* Acquired or congenital facial deformities associated with bony defects or facial asymmetry.\n* Patients requiring patient-specific 3D-printed titanium implants for maxillofacial reconstruction.\n* Aesthetic indications requiring custom facial implant design, including microgenia (chin retrusion).\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Active pathological lesions at the time of enrollment.\n* Age below 18 years.\n* History of radiotherapy within 12 months prior to enrollment.\n* Chronic untreated vitamin D deficiency.\n* Uncontrolled diabetes mellitus.\n* Inability or unwillingness to comply with follow-up requirements.","ALL","18 Years","60 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","This clinical study aims to evaluate the effectiveness of patient-specific 3D-printed titanium facial implants in the reconstruction and aesthetic correction of facial defects. The study will include patients presenting with congenital, traumatic, or post-surgical facial deformities requiring reconstructive intervention.\n\nEligible participants will undergo preoperative clinical assessment and radiological imaging to design customized implants using computer-aided design (CAD) and 3D printing technology. The implants will be fabricated from medical-grade titanium and surgically placed according to standardized maxillofacial reconstructive protocols.\n\nPostoperative follow-up will assess functional outcomes, implant stability, complication rates, and aesthetic improvement over a defined observation period. Outcome evaluation will include clinical examination and patient-reported satisfaction measures.\n\nThe objective of this study is to determine whether patient-specific 3D-printed titanium implants provide reliable functional restoration and improved aesthetic outcomes in facial reconstruction compared to conventional reconstructive techniques.",[28,29,30,31,32,33],"Hemifacial Microsomia","Mucormycosis","Oral Squamous Cell Carcinoma","Microgenia","Facial Asymmetry","Fibrous Dysplasia",[35],"3D-Printed Titanium Implant * Facial Reconstruction","RECRUITING","2026-06-11",{"date":39,"type":40},"2026-06-17","ACTUAL",{"date":42,"type":40},"2026-04-26",{"date":44,"type":22},"2026-11-01",{"name":46,"class":47},"Tishreen University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":48},"100636749","fibrous-dysplasia-an-epidemiological-and-correlational-evaluation-of-multimodal-data-100636749","NCT07569731","Fibrous Dysplasia: An Epidemiological and Correlational Evaluation of Multimodal Data","Fibrous Dysplasia: An Epidemiological and Correlational Study of Anthropometric, Clinical, Treatment, and Genetic Data","FIBR DYSPLASIA","Inclusion Criteria:\n\n* All patients affected by Fibrous Dysplasia, McCune-Albright syndrome and Mazabraud syndrome (retrospectively included from 2009)\n* Availability of clinical and radiological data collected during their recovery at the IOR\n* Availability of tumor tissue in the biobank in sufficient quantity and quality\n\nExclusion Criteria:\n\n* Patients who do not meet the inclusion criteria",{"count":58,"type":22},200,"OBSERVATIONAL","Fibrous dysplasia is a benign, pseudotumoral, genetic but non-hereditary condition characterized by the presence of one or more areas of abnormal bone development in which the normal structure is replaced by fibrous tissue. It is an extremely heterogeneous condition, as it can be monostotic, polyostotic, or panostotic, or it may occur within the context of more complex syndromes such as McCune-Albright syndrome (in which polyostotic fibrous dysplasia is associated with café-au-lait spots and precocious puberty) or Mazabraud syndrome (in which intramuscular myxomas are present).\n\nThis condition is caused by post-zygotic missense mutations, so it is never hereditary, and the affected individual will constitute a so-called \"genetic mosaic,\" a fact that explains the wide variability in the localization of the pathological areas. The mutations in question occur in a gene (GNAS) located on chromosome 20 (20q13.2-13.3); this gene encodes a G protein with GTPase activity, the function of which is consequently impaired.\n\nThe aim of this study is to evaluate in detail the characteristics of the patients, their hospitalizations, and related interventions. Given the rarity of the condition, such investigations are often conducted on very limited datasets. The present study is expected to include over 200 patients, providing a comprehensive picture.\n\nAn additional aim is to assess the impact of somatic mutations in the GNAS gene and their impact in terms of clinical manifestations.",[33,62,63,64],"Fibrous Dysplasia of Bone","Fibrous Dysplasia\u002FMcCune-Albright Syndrome","Mazabraud Syndrome",[33,66,64,67,68,69],"McCune-Albright Syndrome","Surgical procedures","GNAS","Pain","2026-05-07",{"date":72,"type":40},"2026-05-12",{"date":74,"type":40},"2022-05-12",{"date":76,"type":22},"2026-06-30",{"name":78,"class":47},"Istituto Ortopedico Rizzoli",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":85,"targetDuration":87,"studyType":59,"phases":4,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":48},"100303552","fibrous-dysplasia-mccune-albright-syndrome-patient-registry-100303552","NCT03231644","Fibrous Dysplasia, McCune-Albright Syndrome Patient Registry","Inclusion Criteria any one or more of the following:\n\n* clinical diagnosis of fibrous dysplasia\n* clinical diagnosis of McCune-Albright syndrome\n* clinical diagnosis of Mazabraud's syndrome",{"count":86,"type":22},600,"2 Years","The FD\u002FMAS Patient Registry is an IRB-approved research study that that invites the patients and families to help answer some of the biggest questions about FD\u002FMAS by completing questionnaires about their lives with FD or MAS.\n\nHave you enrolled in the FD\u002FMAS Patient Registry yet? Are you up-to-date on your surveys? Take a trip to www.fdmasregistry.org today to learn more about the project, enroll, complete your surveys, or make sure you aren't due to provide more info!\n\nThe FD\u002FMAS Patient Registry: Your story powers research.",[33,90,64],"McCune Albright Syndrome",[33,66,92,93],"Mazabrauds","FD\u002FMAS","2025-08-07",{"date":96,"type":40},"2025-08-12",{"date":98,"type":40},"2016-10-31",{"date":100,"type":22},"2028-10",{"name":102,"class":47},"Tovah Burstein",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":113,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":48},"100513484","phase-4-denosumab-for-the-treatment-of-fibrous-dysplasiamccune-albright-syndrome-in-adults-defid-100513484","NCT05966064","DEnosumab for the Treatment of FIbrous Dysplasia\u002FMcCune-Albright Syndrome in Adults (DeFiD)","DEnosumab for the Treatment of FIbrous Dysplasia\u002FMcCune-Albright Syndrome in Adults (DeFiD): a Randomized Double-blind Placebo-controlled Trial","DeFiD","Inclusion Criteria:\n\n* Symptomatic patients with established diagnosis of FD\u002FMAS and closed growth plates(\\>18 years)\n* Pain in the region of an FD localization, not responding to adequate pain treatment and without mechanical component e.g. impending fracture\n* Pain score from FD lesion for maximum or average pain on VAS ≥ 4\n* Increased lesional activity defined as increased bone turnover markers (ALP, P1NP or CTX) or increased activity on Na\\[18F\\]-PET\u002FCT or bone scintigraphy in at least one lesion\n* Normal levels of calcium, parathyroid hormone and vitamin D (supplementation is allowed)\n* Treated hypophosphatemia (defined as \\>0.7 at two separate measures)\n* good dental health (last check within the last 12 months)\n\nExclusion Criteria:\n\n* Active pregnancy wish, pregnancy or nursing\n* Pain not related to FD\n* Uncontrolled endocrine disease\n* Untreated vitamin D deficiency, hypocalcemia or hypophosphatemia\n* Previous use of bisphosphonates or Dmab \\\u003C 6 months before inclusion ('6 months wash out')\n* Previously reported severe side effects on Dmab\n* Inability to fulfil study requirements\n* Poor untreated dental health without intention to get treatment\n* Treatment with other bone influencing drugs, such as high doses corticosteroids",{"count":112,"type":22},82,[114],"PHASE4","Fibrous Dysplasia\u002FMcCune-Albright syndrome (FD\u002FMAS) is a rare disease, consisting of the replacement of normal bone tissue with fibrous tissue. FD lesions may be isolated in one or more bones or may be associated with endocrinopathies in McCune-Albright syndrome. Bone lesions constitute of weak bone tissue, leading to higher risk of fractures, pain and decreased quality of life. There is no cure for FD lesions and current therapies failed to soothe patients' complaints or to display any effect on progression of the lesions on imaging. However, the RANKL-inhibitor Denosumab demonstrated encouraging results in mouse models and in off-label clinical use, leading to clinical, biochemical and radiographical improvements.\n\nStudy's aim is to investigate whether 3-monthly Denosumab will improve the clinical, radiological and biochemical manifestations of FD bone lesions.",[33,90],"2025-01-28",{"date":119,"type":40},"2025-01-29",{"date":121,"type":40},"2023-06-13",{"date":123,"type":22},"2028-12",{"name":125,"class":47},"Natasha Appelman-Dijkstra"]